NewAmsterdam Pharma (NAMS) Intangibles (2022)
NewAmsterdam Pharma (NAMS) reported Intangibles of $84.8 million for Q4 2022.
NewAmsterdam Pharma (NAMS) Intangibles (2022) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 1 years of Intangibles data on file, last reported at $84.8 million in Q4 2022.
- For the quarter ending Q4 2022, Intangibles changed N/A year-over-year to $84.8 million; the trailing twelve-month figure through Dec 2022 stood at $84.8 million (changed N/A YoY), and the FY2022 full-year result was $84.8 million, changed N/A from the prior year.
- Intangibles steadied at $84.8 million in Q4 2022.
- In the past five years, Intangibles ranged from a high of $84.8 million in Q4 2022 to a low of $84.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 11,640.44 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 61.68 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 55.80 Mn |
| 10 | NewAmsterdam Pharma | 3.64 Bn | 3.64 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 84.84 Mn |